(Q38027731)

27 August 2017

title

Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment (English)

1 reference

27 August 2017

0 references

1 reference

cognitive dysfunction

1 reference

4

Dag Aarsland

1 reference

27 August 2017

3

Clive Ballard

1 reference

27 August 2017

2

Eric Westman

1 reference

27 August 2017

Per Svenningsson

1

1 reference

27 August 2017

publication date

1 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

11

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

697-707

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

27 August 2017

1 reference

7 January 2021

The economic impact of cognitive impairment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Patients with Parkinson's disease dementia stay in the hospital twice as long as those without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

How well do we recognise non-motor symptoms in a British Parkinson's disease population?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

A systematic review of prevalence studies of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Predictors of survival in patients with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Risk of dementia in Parkinson's disease: a community-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The natural history of treated Parkinson's disease in an incident, community based cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The effect of age of onset of PD on risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The rate of cognitive decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Nonlinear decline of mini-mental state examination in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Longitudinal changes in cognition in Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Clinical subtypes of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The progression of pathology in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Characterizing mild cognitive impairment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Association between cognition and function in patients with Parkinson disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Neuropsychological deficits associated with diffuse Lewy body disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Neuropathology of dementia in Parkinson's disease: A prospective, community-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cognitive status correlates with neuropathologic stage in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Parkinson disease with dementia: comparing patients with and without Alzheimer pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Differences in neuropathologic characteristics across the Lewy body dementia spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Familial occurrence of dementia and parkinsonism: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

A Pilot Study Examining Associations between DYRK1A and a-Synuclein Dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Genetic influences on cognitive decline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Quantitative EEG as a predictive biomarker for Parkinson disease dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies. A comparison with Alzheimer's disease and Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Neurodegeneration across stages of cognitive decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Ventricular enlargement and mild cognitive impairment in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

White matter lesions in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Regional cerebral blood flow in Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Grey matter atrophy in early versus late dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Multimodal classification of Alzheimer's disease and mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Clinical diagnostic criteria for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Parkinson's disease dementia can be easily detected in routine clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Network correlates of the cognitive response to levodopa in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Association between amantadine and the onset of dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Therapeutic potential of histamine H3 receptor antagonists in dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Effects of working-memory training on striatal dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970152-7

7 January 2021

10.1016/S1474-4422(12)70152-7

Identifiers

DOI

1 reference

release_xzd4stivmzeeznb4nps6s5wwwy

27 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xzd4stivmzeeznb4nps6s5wwwy

24 November 2022

mapped directly with Wikidata item

1 reference